ATA+, anti-topoisomerase-I positive sufferers (N=24); ATA+(a), ATA+groupa (N=11); ATA+(b), ATA+groupb (N=13); ACA+, anti-centromere positive sufferers (N=18); ARA+, anti-RNA polymerase-III positive sufferers (N=5); ATA+, anti-topoisomerase-I positive sufferers; ATA+(a), anti-topoisomerase-I positive sufferers group a; ATA+(b), anti-topoisomerase-I positive sufferers group b; CDH2, cadherin 2; CDH5, VE-cadherin; CISD1, CDGSH iron sulphur domains 1; EIF2B3, eukaryotic translation initiation aspect 2B subunit gamma; EPS15, epidermal development aspect receptor pathway substrate 15; FKBP11, FKBP prolyl isomerase 11; HC, healthful handles (N=20); ICAM-1, intercellular adhesion molecule 1; ITGA3, integrin alpha-3; NRBP1, nuclear receptor-binding proteins; P4HA2, prolyl 4-hydroxylase subunit alpha-2; PNN, desmosome linked proteins; RAE1, Rae1 RNA export 1; SEL1L, adaptor subunit of SYVN1 ubiquitin ligase; SNRPA, little nuclear ribonucleoprotein polypeptide A; STAM, indication transducing adaptor molecule; STK24, serine/threonine-protein kinase 24; TPP1, tripeptidyl-peptidase 1; TTN, titin
ATA+, anti-topoisomerase-I positive sufferers (N=24); ATA+(a), ATA+groupa (N=11); ATA+(b), ATA+groupb (N=13); ACA+, anti-centromere positive sufferers (N=18); ARA+, anti-RNA polymerase-III positive sufferers (N=5); ATA+, anti-topoisomerase-I positive sufferers; ATA+(a), anti-topoisomerase-I positive sufferers group a; ATA+(b), anti-topoisomerase-I positive sufferers group b; CDH2, cadherin 2; CDH5, VE-cadherin; CISD1, CDGSH iron sulphur domains 1; EIF2B3, eukaryotic translation initiation aspect 2B…